Allez Health Raises $60M in Series A+
Summary
The company intends to use the funds to accelerate growth towards pivotal trials, to support regulatory approval filings, and to scale manufacturing operations. Led by CEO Leif Bowman, Allez Health provides a CGM biosensor platform with sensor technology that is intended to enhance performance and user experience. Since its inception, it has accomplished several milestones including seven issued patents and over 40 pending patent applications, over 80 clinical studies aggregating more than 1,500 users, and a pivotal study in 120 insulin users. Having completed the pivotal study and having secured key strategic investment as well as select distribution and manufacturing arrangements, Allez Health expects to accelerate its progress toward commercialization in multiple global markets, assuming the receipt of the regulatory approvals and the continued availability of capital. The Allez Health sensor is an investigational device that is not yet cleared or approved by the U.S. Food and Drug Administration or any other regulatory authority.